| 高彦君,姚 颐,宋启斌.发性肝癌索拉非尼耐药机制的研究进展[J].肿瘤学杂志,2019,25(9):836-840. |
| 发性肝癌索拉非尼耐药机制的研究进展 |
| Research Progress in Mechanisms of Sorafenib Resistance in Hepatocellular Carcinoma |
| 投稿时间：2019-01-07 |
| DOI：10.11735/j.issn.1671-170X.2019.09.B015 |
|
 |
| 中文关键词: 原发性肝细胞癌 索拉非尼 耐药 肿瘤干细胞 肿瘤微环境 |
| 英文关键词: |
| 基金项目: |
|
| 摘要点击次数: 1888 |
| 全文下载次数: 437 |
| 中文摘要: |
| 摘 要：多激酶抑制剂索拉非尼是被美国食品药品监督管理局批准的用于治疗晚期肝癌的一线分子靶向药物，然而，该药在肝癌治疗中存在原发性或获得性的耐药现象，影响了肝癌的疗效。目前研究发现，除肿瘤细胞、肿瘤干细胞本身的耐药机制外，肿瘤微环境中的免疫细胞、基质细胞等，可通过分泌特定细胞因子或通过直接接触作用、缺氧、自噬等，在肝癌对索拉非尼的耐药中起到关键性的作用。全文总结了原发性肝癌对索拉非尼耐药机制的研究进展，旨在为临床上肝癌的治疗提供新的策略。 |
| 英文摘要: |
| Abstract：Sorafenib，a multikinase inhibitor with antiproliferative，antiangiogenic and proapoptotic properties，constitutes the effective first-line drug approved by FDA for the treatment of advanced hepatocellular carcinoma(HCC). However，primary or acquired drug resistance affects the efficacy of sorafenib in the treatment. In addition to the resistance of tumor cells and cancer stem cells，the immune cells，stromal cells and other components of tumor microenvironment(TME) also play a key role in the resistance of HCC to sorafenib through specific cytokines，direct contact，hypoxia，autophagy，or other mechanisms. This article summarizes the research progress in mechanisms of resistance to sorafenib，to provide information for new clinical treatment strategy of hepatocellular carcinoma. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|